Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679445 | 0.75 | PPARG (0.47) | CNR2NPC1RAB9AMAPTTP53 | |
| SCHEMBL2717815 | 0.73 | ALDH1A1 (0.50) | NPC1RAB9AMAPTHDAC1HDAC6 | |
| SCHEMBL18808346 | 0.72 | EGFR (0.63) | NPC1RAB9AMAPTHPGDMAPK1 | |
| SCHEMBL4785028 | 0.72 | NPC1 (0.48) | NPC1RAB9AMAPTALDH1A1KMT2A | |
| SCHEMBL9979193 | 0.72 | ALDH1A1 (0.62) | NPC1RAB9AMAPTTP53HPGD | |
| SCHEMBL21348486 | 0.70 | SMN1; SMN2 (0.60) | NPC1RAB9AMAPTTP53HPGD | |
| SCHEMBL5543814 | 0.70 | MAPT (0.60) | NPC1RAB9AMAPTTP53HPGD | |
| SCHEMBL3011416 | 0.70 | NPC1 (0.44) | NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL4319038 | 0.70 | MAPT (0.64) | NPC1RAB9AMAPTTP53HPGD | |
| SCHEMBL8996654 | 0.70 | MAPT (0.64) | NPC1RAB9AMAPTTP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1386913-B1 | PYRROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1386913-B1 | PYRROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20040162331-A1 | Pyrrole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-08-19 | — | — | US | disclosed |
| EP-1386913-A1 | PYRROLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162331-A1 | Pyrrole derivative | SLC5A1, GLP1R, SLC5A2 | CNR2 3680/4885NPC1 2030/4885RAB9A 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.